Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARES: Safety Surveillance of DEFINITY in Echocardiography
NCT00625365Phase 4Completed
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Feb 2008
- Primary completion
- May 2009
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perflutren lipid microspheres in cardiovascular disease (CVD), sponsored by Lantheus Holdings, Inc. Primary endpoint: The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration at 30 months. Started Feb 2008; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00625365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625365.